Emerging treatments
Biological therapies
Research is currently focused on new treatment regimens that incorporate personalized biological therapies for high-risk renal tumors.[3] Limitations to progressing these therapies include the rarity of clinical cases, the genetic heterogeneity of Wilms tumor, and the low number of actionable somatic mutations. Identification of robust prognostic factors requires extensive international collaborative studies because of the low proportion of individuals with Wilms tumor who relapse or die.[98] Patients with relapsed Wilms tumor should undergo thorough molecular characterization and be enrolled in protocols or trials with systematic data collecting and reporting.[101]
Use of this content is subject to our disclaimer